Studies of HNSCCs by cancer site, geographic location of study, and overall prevalence of PV
| Site . | Geographic location . | No. studies . | No. cases . | Overall HPV prevalence (95% CI) . |
|---|---|---|---|---|
| Oral cavity | Australia, Canada, China, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, Taiwan, United Kingdom, United States, Venezuela | 35 | 2,642 | 23.5 (21.9-25.1) |
| Oropharynx | Australia, Canada, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, United States | 27 | 969 | 35.6 (32.6-38.7) |
| Larynx* | Canada, Cuba, Denmark, Finland, France, Germany, Greece, India, Italy, Japan, Netherlands, Norway, Spain, Slovenia, Sweden, Switzerland, United Kingdom, United States | 35 | 1,435 | 24.0 (21.8-26.3) |
| Overall | As listed above | 60† | 5,046 | 25.9 (24.7-27.2) |
| Site . | Geographic location . | No. studies . | No. cases . | Overall HPV prevalence (95% CI) . |
|---|---|---|---|---|
| Oral cavity | Australia, Canada, China, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, Taiwan, United Kingdom, United States, Venezuela | 35 | 2,642 | 23.5 (21.9-25.1) |
| Oropharynx | Australia, Canada, Cuba, Finland, France, Germany, India, Ireland, Italy, Japan, Netherlands, Norway, Poland, Spain, Slovenia, Sudan, Sweden, Switzerland, United States | 27 | 969 | 35.6 (32.6-38.7) |
| Larynx* | Canada, Cuba, Denmark, Finland, France, Germany, Greece, India, Italy, Japan, Netherlands, Norway, Spain, Slovenia, Sweden, Switzerland, United Kingdom, United States | 35 | 1,435 | 24.0 (21.8-26.3) |
| Overall | As listed above | 60† | 5,046 | 25.9 (24.7-27.2) |